6. パーキンソン病 Parkinson disease Clinical trials / Disease details
臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04373317 (ClinicalTrials.gov) | May 1, 2022 | 29/4/2020 | Pimavanserin vs. Quetiapine for the Treatment Parkinson's Psychosis | CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP) | Parkinson's Disease Psychosis | Drug: Pimavanserin;Drug: Quetiapine | VA Office of Research and Development | NULL | Not yet recruiting | 40 Years | N/A | All | 358 | Phase 4 | United States |
| 2 | EUCTR2021-000041-40-NL (EUCTR) | 22/02/2022 | 10/11/2021 | A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action | A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action - Microdosing and Parkinson’s disease | Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Psilocybin INN or Proposed INN: Psilocybine Product Name: Ketamine INN or Proposed INN: KETAMINE | Maastricht University | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 34 | Phase 2 | Netherlands | ||
| 3 | NCT05103618 (ClinicalTrials.gov) | February 1, 2022 | 21/10/2021 | Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA | Evaluating the Physiological and Psychological Effects of a Novel Meditation Technique on Cerebral Activity Measured With Functional Magnetic Resonance Imaging(fMRI) and F-18 Fluorodopa PET Imaging | Parkinson Disease;Idiopathic Parkinson Disease | Drug: [F-18] Fluorodopa Positron Emission Tomography;Behavioral: OM Meditation | Andrew Newberg | NULL | Not yet recruiting | 25 Years | N/A | All | 80 | Phase 2 | United States |
| 4 | NCT04933513 (ClinicalTrials.gov) | September 30, 2021 | 8/6/2021 | Development and Validation of a Scale Measuring Preoperative Expectations in Parkinson's Disease | Development and Validation of a French Scale Measuring Preoperative Expectations of Parkinson's Disease Patients Candidate to Deep Brain Stimulation : the DBS-PS (Deep Brain Stimulation Perception Scale) | Parkinson's Disease | Behavioral: pre DBS patients responding to the DBS-PS scale | Central Hospital, Nancy, France | University Hospital, Bordeaux;Poitiers University Hospital;Assistance Publique - Hôpitaux de Paris;University Hospital, Lille | Not yet recruiting | 18 Years | N/A | All | 22 | France | |
| 5 | NCT04932434 (ClinicalTrials.gov) | August 15, 2021 | 5/5/2021 | Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease | Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study | Parkinson Disease;Depression;Anxiety | Drug: Psilocybin therapy | Joshua Woolley, MD/PhD | NULL | Recruiting | 40 Years | 75 Years | All | 10 | Phase 2 | United States |
| 6 | NCT04829760 (ClinicalTrials.gov) | May 13, 2021 | 31/3/2021 | The Effect of Psyllium and Wheat Bran on Body Weight in People With Parkinson's Disease and Constipation Symptoms | The Effect of Psyllium and Wheat Bran on Body Weight in People With Parkinson's Disease and Constipation Symptoms | Parkinson Disease | Dietary Supplement: Psyllium;Dietary Supplement: Coarse wheat bran;Dietary Supplement: Maltodextrin | University of Florida | NULL | Recruiting | 40 Years | 85 Years | All | 79 | N/A | United States |
| 7 | EUCTR2021-000867-65-DE (EUCTR) | 19/04/2021 | 16/03/2021 | Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed rotigotine-containing transdermal patch in patients with Parkinson's disease | Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed rotigotine-containing transdermal patch in patients with Parkinson's disease | Idiopathic Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] | Product Name: ROT-TDS 8 mg/24 h INN or Proposed INN: ROTIGOTINE Trade Name: Neupro® 8 mg/24 h Product Name: Neupro® 8 mg/24 h INN or Proposed INN: ROTIGOTINE | Luye Pharma Switzerland AG | NULL | Not Recruiting | Female: yes Male: yes | 38 | Phase 2 | Germany | ||
| 8 | NCT04722198 (ClinicalTrials.gov) | October 27, 2020 | 15/1/2021 | Effects of Lactobacillus Plantarum PS128 on Symptoms of Early-onset Parkinson's Disease: a Pilot Study | Effects of Lactobacillus Plantarum PS128 on Symptoms of Early-onset Parkinson's Disease: a Pilot Study | Early Onset Parkinson Disease | Dietary Supplement: PS128 | Professor Lu Neurological Clinic | NULL | Recruiting | 20 Years | 80 Years | All | 20 | N/A | Taiwan |
| 9 | NCT04722211 (ClinicalTrials.gov) | July 6, 2020 | 15/1/2021 | Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease. | Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease. | Parkinson Disease | Dietary Supplement: PS128;Dietary Supplement: placebo | Professor Lu Neurological Clinic | NULL | Recruiting | 45 Years | 80 Years | All | 120 | N/A | Taiwan |
| 10 | NCT04193527 (ClinicalTrials.gov) | June 18, 2020 | 2/12/2019 | A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients | A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls | Parkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP) | Drug: DaTSCAN™ Ioflupane (123I) Injection | GE Healthcare | PPD | Completed | 40 Years | 80 Years | All | 172 | Phase 3 | China |
| 11 | NCT04428112 (ClinicalTrials.gov) | June 5, 2020 | 9/6/2020 | Rural Dementia Caregiver Project | Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related Dementias | Depression;Stress, Psychological;Self Efficacy;Loneliness;Social Isolation;Health Care Utilization;Dementia;Dementia Alzheimers;Dementia of Alzheimer Type;Dementia, Vascular;Dementia Frontal;Dementia, Lewy Body;Dementia, Mixed;Dementia in Parkinsons Disease;Dementia, HIV;Dementia Frontotemporal;Dementia, Multi-Infarct | Behavioral: Building Better Caregivers Workshop;Behavioral: Attention Control | University of California, San Francisco | National Institute on Aging (NIA) | Recruiting | 18 Years | N/A | All | 640 | N/A | United States |
| 12 | EUCTR2019-003962-41-GB (EUCTR) | 23/03/2020 | 06/02/2020 | Trial of Ondansetron as a Parkinson's HAllucinations Treatment: TOP HAT | Trial of Ondansetron as a Parkinson’s HAllucinations Treatment - TOP HAT | Adults aged over 18 years with Parkinson's disease and visual hallucinations MedDRA version: 21.1;Level: LLT;Classification code 10047570;Term: Visual hallucinations;System Organ Class: 100000004873;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] | Trade Name: Ondansetron 8 mg film-coated tablets Product Name: Ondansetron 8 mg film-coated tablets INN or Proposed INN: Ondansetron hydrochloride dihydrate | University College London | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 216 | Phase 2 | United Kingdom | ||
| 13 | EUCTR2019-003623-37-GB (EUCTR) | 12/02/2020 | 02/01/2020 | CANnabidiol for Parkinson’s Disease Psychosis | CANnabidiol for Parkinson’s Disease Psychosis - CAN-PDP | Parkinson's disease psychosis MedDRA version: 20.0;Level: PT;Classification code 10074835;Term: Parkinson's disease psychosis;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02] | Product Name: Cannabidiol Product Code: Cannabidiol INN or Proposed INN: Cannabidiol (CBD) | King's College London | South London and Maudsley NHS Foundation Trust | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 144 | Phase 2 | United Kingdom | ||
| 14 | NCT04292223 (ClinicalTrials.gov) | February 10, 2020 | 28/2/2020 | Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis | A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis | Parkinson Disease Psychosis | Drug: Pimavanserin | ACADIA Pharmaceuticals Inc. | NULL | Active, not recruiting | 40 Years | N/A | All | 53 | Phase 4 | United States |
| 15 | NCT03652870 (ClinicalTrials.gov) | November 1, 2019 | 8/8/2018 | Antidepressants Trial in Parkinson's Disease | A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease | Depression;Parkinson Disease | Drug: Nortriptyline;Drug: Escitalopram;Drug: Placebo | University College, London | London North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS Lothian | Not yet recruiting | 18 Years | 85 Years | All | 408 | Phase 3 | NULL |
| 16 | EUCTR2018-002942-35-GB (EUCTR) | 31/10/2019 | 05/09/2019 | A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo, and standard psychological care, for depression in Parkinson’s disease | A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo and standard psychological care for depression in Parkinson’s Disease - Antidepressants Trial in Parkinson's Disease (ADepT-PD) | Depression in Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10012378;Term: Depression;System Organ Class: 10037175 - Psychiatric disorders MedDRA version: 20.0;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Escitalopram INN or Proposed INN: Escitalopram oxalate Trade Name: Nortriptyline Product Name: Nortriptyline INN or Proposed INN: Nortriptyline hydrochloride | University College London Comprehensive Clinical Trials Unit | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 408 | Phase 3 | United Kingdom | ||
| 17 | NCT04389762 (ClinicalTrials.gov) | June 4, 2019 | 30/4/2020 | PS128 May Improve Off Duration on Parkinson's Disease | Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study | Parkinson Disease | Dietary Supplement: daily ingestion of Lactobacillus plantarum PS128 | Professor Lu Neurological Clinic | NULL | Completed | 40 Years | 80 Years | All | 60 | N/A | Taiwan |
| 18 | NCT03661125 (ClinicalTrials.gov) | April 11, 2019 | 4/9/2018 | SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis | A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis. | Parkinson Disease Psychosis | Drug: Saracatinib;Drug: Placebo Oral Tablet | King's College London | AstraZeneca;King's College Hospital NHS Trust | Recruiting | 40 Years | N/A | All | 30 | Early Phase 1 | United Kingdom |
| 19 | NCT03566589 (ClinicalTrials.gov) | July 2, 2018 | 12/6/2018 | Effects of PS128 on Parkinsonian Symptoms | Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot Study | Parkinson Disease | Dietary Supplement: Lactobacillus plantarum PS128 | Professor Lu Neurological Clinic | NULL | Completed | 40 Years | 80 Years | All | 30 | N/A | Taiwan |
| 20 | ChiCTR1800015331 | 2018-04-01 | 2018-03-23 | Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease | Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease | Parkinson's disease | de novo PD patients:levodopa 4 weeks;de novo PD patients:pramipexole 4 weeks;de novo PD patients:selegiline 4 weeks; | Institute of Psychology, Chinese Academy of Sciences | NULL | Recruiting | 50 | 80 | Both | de novo PD patients:50;de novo PD patients:50;de novo PD patients:50; | China | |
| 21 | NCT02969369 (ClinicalTrials.gov) | December 31, 2016 | 17/11/2016 | A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis | A Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis | Parkinson Disease Psychosis | Drug: SEP-363856;Drug: Placebo capsule | Sunovion | NULL | Completed | 55 Years | 105 Years | All | 39 | Phase 2 | United States |
| 22 | JPRN-UMIN000024859 | 2016/12/14 | 16/11/2016 | The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide. | The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide. - The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide. | Parkinson's disease | Switching from Dopamine agonist to Zonisamide. Intervention period of 12 weeks. | Medical Corporation Abe Neurology Clinic | NULL | Complete: follow-up continuing | 30years-old | Not applicable | Male and Female | 50 | Not applicable | Japan |
| 23 | NCT02762591 (ClinicalTrials.gov) | May 3, 2016 | 3/5/2016 | Expanded Access of Pimavanserin for Patients With PD Psychosis | Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis | Parkinson's Disease Psychosis | Drug: Pimavanserin tartrate | ACADIA Pharmaceuticals Inc. | NULL | Approved for marketing | 40 Years | N/A | All | N/A | NULL | |
| 24 | NCT02103894 (ClinicalTrials.gov) | February 2014 | 12/2/2014 | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects | Alzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;Tauopathies | Drug: [18F]T807 ([18F]MNI-777) | Molecular NeuroImaging | Institute for Neurodegenerative Disorders | Completed | 18 Years | 85 Years | Both | 16 | Phase 1 | United States |
| 25 | NCT01560754 (ClinicalTrials.gov) | October 2012 | 9/3/2012 | Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease | A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA | Parkinson's Disease | Drug: nicotine transdermal patch | James BOYD MD | Michael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, Germany | Active, not recruiting | 30 Years | N/A | Both | 160 | Phase 2 | United States;Germany |
| 26 | NCT01519882 (ClinicalTrials.gov) | March 2012 | 24/1/2012 | Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease | A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Rotigotine on Sleep Efficiency in Patients With Advanced Parkinson's Disease. | Advanced Idiopathic Parkinson's Disease | Other: Placebo;Other: Rotigotine | UCB Pharma SA | NULL | Terminated | 18 Years | N/A | All | 1 | Phase 4 | United Kingdom |
| 27 | EUCTR2011-000056-42-GB (EUCTR) | 07/10/2011 | 11/08/2011 | Sleep efficiency assessed by Polysomnography (PSG sleep lab testing) in advanced Parkinson's disease | A MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ROTIGOTINE ON SLEEP EFFICIENCY IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE - sleep efficiency assessed by polysomnography in advanced Parkinson's Disease | Advanced Parkinson's Disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Neupro 4mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 6mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE Trade Name: Neupro 8mg/24h transdermal patch INN or Proposed INN: ROTIGOTINE | UCB Celltech, UK - Registered Branch of UCB Pharma SA | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom | ||||
| 28 | JPRN-UMIN000005403 | 2011/04/01 | 08/04/2011 | A Multi-center Randomized Placebo-controlled Double-blinded Study for the Efficacy of Donepezil against Psychosis in Parkinson Disease | Parkinson disease | 5mg of donepezil hydrochloride placebo | Designated Research, National Hospital Organization | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 142 | Phase 3 | Japan | |
| 29 | EUCTR2009-015928-28-SE (EUCTR) | 07/10/2010 | 13/08/2010 | A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09 | A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09 | Dyskinesias related to levodopa treatment in Parkinson´s disease | Product Name: Eltoprazine HCl Product Code: Eltoprazine HCl | PsychoGenics Inc | NULL | Not Recruiting | Female: yes Male: yes | 24 | Sweden | |||
| 30 | EUCTR2009-017253-35-GB (EUCTR) | 20/08/2010 | 06/08/2010 | Long-term study of patients who received ProSavin in the PS1/001/07 clinical trial. | A multicentre, open-label extension study to determine the long term safety, tolerability and efficacy of ProSavin® in patients with bilateral, idiopathic Parkinson’s disease | Patients with bilateral, idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ProSavin INN or Proposed INN: ProSavin | Oxford BioMedica (UK) Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 27 | United Kingdom | |||
| 31 | NCT01174004 (ClinicalTrials.gov) | July 2010 | 30/7/2010 | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease | Parkinson's Disease Psychosis | Drug: pimavanserin tartrate;Drug: placebo | ACADIA Pharmaceuticals Inc. | NULL | Completed | 40 Years | N/A | All | 199 | Phase 3 | United States;Canada |
| 32 | JPRN-UMIN000007497 | 2010/01/01 | 14/03/2012 | Trial of molecular hydrogen water in Parkinson disease | Parkinson disease | The subjects should make 1000 ml of molecular hydrogen water which contains 1.6 ppm dissolved hydrogen by Aquerable, and consume for 48 weeks. Placebo water which is not contained molecular hydrogen water made from pseudo-machine. The subjects consume for48 weeks. | Department of Neurology, Juntendo University School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 18 | Not applicable | Japan | |
| 33 | EUCTR2007-003035-22-AT (EUCTR) | 30/03/2009 | 26/05/2008 | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 560 | Phase 2;Phase 3 | Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden | ||
| 34 | EUCTR2008-006045-10-FR (EUCTR) | 06/02/2009 | 24/03/2009 | Effet de la stimulation dopaminergique continue par pompe à apomorphine sur les fluctuations cognitives et psychiques des patients parkinsoniens: étude clinique et métabolique cérébrale par TEP au 18FDG - APO TEP | Effet de la stimulation dopaminergique continue par pompe à apomorphine sur les fluctuations cognitives et psychiques des patients parkinsoniens: étude clinique et métabolique cérébrale par TEP au 18FDG - APO TEP | L’objectif thérapeutique principal dans la maladie de Parkinson est de contrôler les fluctuations motrices. Cependant des fluctuations non motrices (FNM) sont fréquemment observées et semblent corrélées à la sévérité de la maladie. La stabilité dans le temps de l’efficacité du traitement dopaminergique est le moyen le plus pertinent pour améliorer les fluctuations tant motrices que non motrices. MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's | Trade Name: Apokinon | CHU de Rennes | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | France | ||
| 35 | EUCTR2007-003035-22-PT (EUCTR) | 09/01/2009 | 01/07/2008 | A safety and tolerability study of ACP-103 in patients with Parkinson's Disease Psychosis | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | MedDRA version: 18.0;Level: LLT;Classification code 10037241;Term: Psychosis NOS;System Organ Class: 100000004873 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pimavanserin tartrate Product Code: pimavanserin (ACP-103) INN or Proposed INN: Pimavanserin tartrate Other descriptive name: N/A | ACADIA Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Portugal;United States;Ukraine;Austria;Russian Federation;United Kingdom;Italy;India;France;European Union;Canada;Belgium;Sweden | ||
| 36 | EUCTR2007-003035-22-IT (EUCTR) | 07/01/2009 | 23/07/2008 | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease - ACP-103-015 | Psychosis in Parkinson?s Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: primavanserin tartrate Product Code: ACP-103 INN or Proposed INN: primavanserin tartrate | ACADIA PHARMACEUTICALS INC. | NULL | Not Recruiting | Female: yes Male: yes | 486 | Portugal;United Kingdom;Belgium;France;Italy;Austria;Sweden | ||||
| 37 | EUCTR2007-003051-36-BE (EUCTR) | 06/11/2008 | 21/05/2008 | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 280 | Austria;Sweden;Portugal;Spain;Belgium | |||
| 38 | EUCTR2007-003035-22-GB (EUCTR) | 05/11/2008 | 20/12/2007 | A safety and tolerability study of ACP-103 in patients with Parkinson's Disease Psychosis | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease - ACP-103-015 | Psychosis in Parkinson's Disease MedDRA version: 20.0;Level: LLT;Classification code 10037241;Term: Psychosis NOS;System Organ Class: 100000004873 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pimavanserin tartrate Product Code: pimavanserin (ACP-103) INN or Proposed INN: Pimavanserin tartrate Other descriptive name: N/a | ACADIA Pharmaceuticals Inc. | NULL | Not Recruiting | Female: yes Male: yes | 400 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Portugal;Ukraine;Austria;Russian Federation;United Kingdom;Italy;India;France;European Union;Canada;Belgium;Sweden | ||
| 39 | EUCTR2007-003051-36-AT (EUCTR) | 10/09/2008 | 29/04/2008 | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 280 | Portugal;Spain;Austria;Sweden | |||
| 40 | EUCTR2007-003051-36-PT (EUCTR) | 05/09/2008 | 27/05/2008 | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 280 | Portugal;Spain;Austria;Sweden | |||
| 41 | EUCTR2007-003035-22-BE (EUCTR) | 02/09/2008 | 21/05/2008 | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: pimavanserin (ACP-103) INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2;Phase 3 | Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden | ||
| 42 | EUCTR2007-003051-36-ES (EUCTR) | 01/07/2008 | 05/05/2008 | Ensayo multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ACP-103 en el tratamiento de la psicosis en la enfermedad de Parkinson.A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Ensayo multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ACP-103 en el tratamiento de la psicosis en la enfermedad de Parkinson.A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psicosis en la enfermedad de Parkinson.Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 280 | Portugal;Spain;Austria;Sweden | |||
| 43 | EUCTR2007-003051-36-SE (EUCTR) | 30/06/2008 | 16/05/2008 | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 280 | Portugal;Spain;Austria;Sweden | |||
| 44 | EUCTR2007-003035-22-SE (EUCTR) | 11/06/2008 | 16/05/2008 | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: pimavanserin (ACP-103) INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2;Phase 3 | Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden | ||
| 45 | EUCTR2007-004009-93-IT (EUCTR) | 20/05/2008 | 14/07/2008 | Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram | Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram | Depression, anxiety and ICD MedDRA version: 14.1;Level: SOC;Classification code 10037175;Term: Psychiatric disorders;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: CIPRALEX INN or Proposed INN: Escitalopram Trade Name: CIPRALEX INN or Proposed INN: Escitalopram | LUNDBECK ITALIA | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
| 46 | EUCTR2007-002906-23-BG (EUCTR) | 16/04/2008 | 07/07/2008 | A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 280 | United Kingdom;France;Bulgaria | |||
| 47 | NCT00658567 (ClinicalTrials.gov) | March 2008 | 10/4/2008 | A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | Parkinson's Disease Psychosis | Drug: Pimavanserin tartrate (ACP-103) | ACADIA Pharmaceuticals Inc. | NULL | Completed | 40 Years | N/A | All | 123 | Phase 3 | United States;Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden | |
| 48 | EUCTR2007-003035-22-FR (EUCTR) | 29/02/2008 | 15/02/2008 | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 486 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Portugal;France;Belgium;Austria;Italy;United Kingdom;Sweden | ||
| 49 | EUCTR2007-002906-23-GB (EUCTR) | 14/11/2007 | 15/08/2007 | A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 280 | United Kingdom;Bulgaria;France | |||
| 50 | EUCTR2007-002906-23-FR (EUCTR) | 25/10/2007 | 21/08/2007 | A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | Psychosis in Parkinson's Disease MedDRA version: 9.1;Level: LLT;Classification code 10037241;Term: Psychosis NOS | Product Name: Pimavanserin tartrate Product Code: ACP-103 INN or Proposed INN: Pimavanserin tartrate | Acadia Pharmaceuticals Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 280 | United Kingdom;Bulgaria;France | |||
| 51 | EUCTR2007-002874-75-IT (EUCTR) | 10/09/2007 | 14/01/2008 | Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'' - OV-1005 | Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'' - OV-1005 | Psycosis associated to Parkinson's Disease MedDRA version: 9.1;Level: HLT;Classification code 10027361;Term: Mental disorders due to a general medical condition NEC | Product Name: Melperon | OVATION PHARMACEUTICALS INC | NULL | Not Recruiting | Female: yes Male: yes | 90 | Italy | |||
| 52 | NCT00550238 (ClinicalTrials.gov) | July 2007 | 26/10/2007 | A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | Parkinson's Disease Psychosis | Drug: Pimavanserin tartrate (ACP-103) | ACADIA Pharmaceuticals Inc. | NULL | Completed | 40 Years | N/A | All | 459 | Phase 3 | United States;Austria;Belgium;Canada;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom |
| 53 | JPRN-UMIN000000780 | 2007/06/01 | 01/08/2007 | A randomized, double-blind, placebo-controlled, cross-over, multi-center study concerning the efficacy and safety of amantadine hydrochloride in treatment of dyskinesias in Parkinson's disease | Parkinson's disease | An observation period (2 to 3 weeks) An administration of amantadine hydrochloride (27 days) A wash out period (15 days) An administration of placebo (27 days) An observation period (2 to 3 weeks) An administration of placebo (27 days) A wash out period (15 days) An administration of amantadine hydrochloride (27 days) | Comprehensive clinical study group concerning diagnosis, treatment, and prevention of the neurological disorders | Musashi Hospital, National Center of Neurology and Psychiatry, JapanEhime University Hospital | Complete: follow-up complete | 20years-old | 75years-old | Male and Female | 60 | Not applicable | Japan | |
| 54 | NCT00477672 (ClinicalTrials.gov) | June 2007 | 22/5/2007 | A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease | Parkinson's Disease Psychosis | Drug: Pimavanserin tartrate (ACP-103);Drug: Placebo | ACADIA Pharmaceuticals Inc. | NULL | Completed | 40 Years | N/A | All | 298 | Phase 3 | United States;Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom |
| 55 | EUCTR2007-000307-15-IT (EUCTR) | 24/04/2007 | 23/08/2007 | Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease. | Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease. | Psicosi associata al morbo di Parkinson MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's | Product Name: Melperon INN or Proposed INN: melperon | OVATION PHARMACEUTICALS INC | NULL | Not Recruiting | Female: yes Male: yes | 90 | Italy | |||
| 56 | NCT00354133 (ClinicalTrials.gov) | July 2006 | 19/7/2006 | Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease | The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study) | Parkinson Disease | Device: Kinetra and Soletra (neurostimulator, Medtronic);Drug: Best Medical Treatment | German Parkinson Study Group (GPS) | University Hospital Schleswig-Holstein;Assistance Publique - Hôpitaux de Paris;KKS Netzwerk | Active, not recruiting | 18 Years | 60 Years | All | 251 | Phase 4 | France;Germany |
| 57 | NCT00125138 (ClinicalTrials.gov) | July 2005 | 27/7/2005 | Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease | Safety and Efficacy of Melperone in the Treatment of Patients With Psychosis Associated With Parkinson's Disease | Parkinson's Disease;Psychotic Disorders | Drug: Melperone HCl;Drug: Placebo | Lundbeck LLC | NULL | Completed | N/A | N/A | All | 90 | Phase 2 | United States;India;Italy |
| 58 | EUCTR2004-002608-13-GB (EUCTR) | 16/05/2005 | 19/04/2005 | Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease | Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease | Parkinson's Disease with psychosis | Trade Name: Seroquel Product Name: Seroquel Trade Name: Seroquel Product Name: Seroquel | King’s College London & King’s College Hospital | NULL | Not Recruiting | Female: yes Male: yes | 60 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom | ||
| 59 | NCT01518309 (ClinicalTrials.gov) | November 17, 2004 | 16/12/2008 | An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients | An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients | Parkinson's Disease Psychosis | Drug: pimavanserin tartrate (ACP-103) | ACADIA Pharmaceuticals Inc. | NULL | Completed | N/A | N/A | All | 39 | Phase 2 | United States |
| 60 | NCT00095810 (ClinicalTrials.gov) | July 2003 | 9/11/2004 | Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease | An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease | Parkinson's Disease;Psychoses | Drug: aripiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka America Pharmaceutical | Completed | 50 Years | N/A | Both | 50 | Phase 4 | United States |
| 61 | NCT00056524 (ClinicalTrials.gov) | February 2003 | 15/3/2003 | Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter) | An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect. | Alzheimer's Disease;Stroke;Parkinson's Disease;Traumatic Brain Injury | Drug: AVP-923 | Avanir Pharmaceuticals | NULL | Completed | 18 Years | 80 Years | Both | 600 | Phase 3 | United States |
| 62 | NCT00117819 (ClinicalTrials.gov) | March 2001 | 30/6/2005 | A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease | Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome | Parkinsonian Syndrome | Drug: [123I]ß CIT and SPECT imaging | Institute for Neurodegenerative Disorders | Indiana University;Albany Medical College | Completed | 22 Years | N/A | Both | 232 | Phase 2 | United States |
| 63 | NCT00004826 (ClinicalTrials.gov) | October 1993 | 24/2/2000 | Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease | Parkinson Disease | Drug: clozapine | Memorial Hospital of Rhode Island | NULL | Completed | N/A | N/A | Both | 60 | N/A | NULL |